RxDoctor Payments Data

Michelle Long

Gastroenterology · Boston, MANPI 1194952663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,750 of the $30,320 with a category attached, or 91.5%. Novo Nordisk accounts for 98.6% of it on its own, with 1 other manufacturer making up the rest. 2022 is the largest year on record at $17,933, more than ten times the $411 reported in 2019.

$30,320in general payments, 2019–2025

Across 13 payments — averaging $2332.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$30K
  • Gilead$411
$600,776in research payments, 2019–2025

Across 230 payments — averaging $2612.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$320K
  • Intercept Pharmaceuticals, Inc.$123K
  • Intercept Pharma Europe Ltd.$80K
  • E.r. Squibb & Sons, L.L.C.$32K
  • Astrazeneca UK Limited$20K
  • AbbVie$12K
  • plus $14K from 2 others

What the payments were for

  • Consulting fees$27,75092%
  • Travel & lodging$1,9056%
  • Food & beverage$6652%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$29,909
Gilead2$411

How this compares

$30,320 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts →

Other gastroenterology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →